Menu
ncarol.com
  • Home
  • Business
  • Financial
  • Finance
  • Nyse
  • Loans
  • Yacht Buyer
  • Stocks
  • Banking
ncarol.com

'Spot Detective' – Check your spots this summer
ncarol.com/10200678

Trending...
  • Desert Mountain Club Earns Prestigious Blue Zones Approved™ Triple Designation, a New Standard for Well-Being in a Luxury Lifestyle Community
  • CNCPW Divulga Dados de Liquidez do 1º Trimestre: Confirma 100% de Reservas e Atualiza Protocolos de "Saque CNCPW" Contra Fluxos Ilícitos
  • WinkBeds High-Performance Hybrid Mattresses Debut at Sleep Basil Denver With In-Store Comfort Testing
The Spot Detective - who are they The Spot Detective - freckle
The latest campaign urging Australians to get their skin checked

MELBOURNE, Australia & SYDNEY - ncarol.com -- OncoBeta, a leading medical device company specialising in innovative epidermal radioisotope therapies for non-melanoma skin cancer, has launched The Spot Detective campaign to rally Australians in the fight against skin cancer this summer.

With two out of three Australians diagnosed with skin cancer before the age of 701, it is vital for all Australians to have regular skin checks. The Spot Detective campaign is encouraging Australians to visit a Spot Detective – their GP, dermatologist or skin health specialist – to have their spots assessed and to learn about the various treatments available for those diagnosed with non-melanoma skin cancer.

Skin cancer occurs when skin cells are damaged, often from overexposure to ultraviolet (UV) radiation from the sun. There are three main types of skin cancer: basal cell carcinoma (BCC); squamous cell carcinoma (SCC) and melanoma.2 Australia has one of the highest melanoma rates in the world1, with one Australian dying from melanoma every six hours.3 A skin check can save your life.

OncoBeta's Australian Medical Director, Dr Sam Vohra, says, "Thankfully most skin cancers are treatable and most of us will know someone who has had a skin cancer. Today, there are a range of treatments available to patients in addition to surgery, some of which are painless*, only needing a single session† and non-invasive."4-6

The Spot Detective campaign is asking Australians to take action: if they see a skin spot that is suspicious, new, oddly shaped or has changed in colour then it's time to get it checked. The campaign includes a series of LIVE reads across 2GB and WSFM in Sydney and 3AW and Gold 104.3 in Melbourne, as well as a social media and digital marketing campaign, and free skin check pop-ups at various locations.

More on ncarol.com
  • Nashville International Chopin Piano Competition Launches First Amateur Edition
  • Bentson Copple Patterson & Associates Announces Orthodontic Practice & Career Transition Seminar
  • Market Value Enhancement From 2 Important New US Patents Issued for Strengthening Hair Enzyme Booster Technology to Caring Brands (NAS DAQ: CABR)
  • HELM Audio™ Partners with PQCrypto to Future-Proof Children's Hearing and Safety Data Using Post-Quantum Cryptography
  • Wala Blegay to Announce Run for Congress in Maryland's 5th District on Feb. 4

"With one of the highest incidences of skin cancer in the world, Australians need to be vigilant with their skin. The Spot Detective campaign is a timely reminder to make sure you are protecting yourself from the sun, and if you notice any changes to your skin, check in with a skin health specialist," added Dr Vohra.

Another health initiative from OncoBeta, this public awareness campaign also encourages anyone diagnosed with non-melanoma skin cancer to be well informed about all treatments and discuss their most suitable options with a healthcare professional. OncoBeta's skin cancer therapy which utilises the rhenium-188 isotope is now available at private clinics at Melbourne and Sydney. Patients with difficult anatomic localisations of a tumour, such as the ear, nose or anywhere on the face, and those with larger lesions problematic for plastic surgery, may benefit from this non-invasive solution.

To find out more information on skin cancer, and to learn what treatments are available, visit: www.spotdetective.com.au

About OncoBeta® GmbH
OncoBeta® GmbH, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:

More on ncarol.com
  • Nufabrx Raises $5M in Oversubscribed Round Led by Meltzer Capital
  • Luxury Lake-View Home Launches in Kissimmee's Bellalago community, Offering Privacy, Space, and Florida Resort-Style Living
  • Sleep Basil Launches Revamped Diamond Mattress Collection Page, Highlighting Performance, Craftsmanship, and Personalized Comfort
  • Sleep Basil Curates a Clearer Brooklyn Bedding Experience for Performance-Minded Denver Sleepers
  • Nevada Man Launches Nationwide Animal Abuse Registry

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

*No reported pain.3
†
Complete tumour regression in 98.5% of lesions treated.

References:
1. Cancer Council. Understanding Skin Cancer. January 2020. https://www.cancercouncil.com.au/ (accessed October 2022).
2. Skin Cancer. Available at https://www.mayoclinic.org/diseases-conditions/skin-cancer/symptoms-causes/syc-20377605 [Accessed October 2022]
3. Melanoma Institute Australia. Melamoma Facts. https://melanoma.org.au/about-melanoma/melanoma-facts/ (accessed October 2022).
4. Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48(5):1511–1521.
5. Cipriani C, et al. J Dermatol Treat. 2020; DOI: 10.1080/09546634.2020.1793890.
6. Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.

Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Kaltra Expands Microchannel Innovation to Deliver Lower Refrigerant Charge
  • Georgia's Lanier Islands Resort Tees Up for a New Era of Golf in Spring 2026
  • Eagle Americas Expands Into the Western U.S. With High West Machine Tool
  • Desert Mountain Club Earns Prestigious Blue Zones Approved™ Triple Designation, a New Standard for Well-Being in a Luxury Lifestyle Community
  • Outsports announces record-breaking number of LGBTQ+ athletes at 2026 Milan Winter Olympics
  • Sheffield Clinic Highlights Safe, Inclusive Laser Hair Removal While Improving Access
  • Appliance EMT Partners with Kids Motel Ministry in Metro Atlanta
  • CNCPW Divulga Dados de Liquidez do 1º Trimestre: Confirma 100% de Reservas e Atualiza Protocolos de "Saque CNCPW" Contra Fluxos Ilícitos
  • Tech Workers Are Escaping "Forever Layoffs" By Becoming Their Own Boss
  • Heritage at South Brunswick Celebrates First Home Closing and Strong Sales Momentum
  • WinkBeds High-Performance Hybrid Mattresses Debut at Sleep Basil Denver With In-Store Comfort Testing
  • Tampa Nonprofit Expands Recovery Services for Men in Crisis With New Farm Program in Plant City
  • IYKYK! Coffee Lab Thriving in Huntington Beach, Blending Elevated Coffee, Matcha, Music, and Community
  • Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
  • Sacred Surrogacy, CFC, and Egghelpers Launch Women's Retreats
  • Stipenda Appoints David Epstein as Chief Operating Officer
  • Woven Wire Mesh as a Durable Filter Medium for Industrial Filtration Systems
  • FondoQuantaX Completes Core Trading Engine Upgrade: Refactoring High-Concurrency Architecture with AI Adaptive Algorithms to Navigate Market Extremes
  • As Paris Hilton Reclaims Her Icon Status, "Pretty Pop Star" Reemerges to Battle the Age of AI Music
  • Food Journal Magazine Is Shaping the Conversation Around Los Angeles Food in 2026
_catLbl0 _catLbl1

Popular on ncarol.com

  • $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway - 122
  • UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT - 121
  • David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District - 110
  • International Law Group Expands Emergency Immigration Consultations for Somali Minnesotans Amid ICE Actions - 103
  • UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
  • Sharpe Automotive Redefines Local Car Care with "Transparency-First" Service Model in Santee
  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
  • Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
  • Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP

Similar on ncarol.com

  • Chronic Boss Awards Scholarships to Student Founders Living with Chronic Conditions
  • Bentson Copple Patterson & Associates Announces Orthodontic Practice & Career Transition Seminar
  • Market Value Enhancement From 2 Important New US Patents Issued for Strengthening Hair Enzyme Booster Technology to Caring Brands (NAS DAQ: CABR)
  • Wala Blegay to Announce Run for Congress in Maryland's 5th District on Feb. 4
  • Nufabrx Raises $5M in Oversubscribed Round Led by Meltzer Capital
  • Sleep Basil Launches Revamped Diamond Mattress Collection Page, Highlighting Performance, Craftsmanship, and Personalized Comfort
  • Sleep Basil Curates a Clearer Brooklyn Bedding Experience for Performance-Minded Denver Sleepers
  • purelyIV Expands Concierge Wellness Platform with New IV Therapies, Memberships, and Digital Experience
  • CCHR: Europe Rejects Forced Psychiatry—Landmark Vote Declares Coercive Practices Incompatible with Human Rights
  • Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute